← All trials
NCT00893555
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2009
- Primary completion
- Nov 1, 2016
- Completion date
- Jan 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 189
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of GroningenLead sponsor
- University of GroningenOverall official - principal investigator
- University of GroningenSponsor investigator
- University of GroningenStudy chair
- Meander Medical CenterCollaborator
- Leiden UniversityCollaborator
- Utrecht UniversityCollaborator
- Radboud UniversityCollaborator
- Haga Hospital, LeywegCollaborator
- Free University of AmsterdamCollaborator
- Klinikum OldenburgCollaborator
- St. Antonius Hospital, NieuwegeinCollaborator
- University of AmsterdamCollaborator
- Erasmus University RotterdamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.